Related Experiment Video

Updated: Aug 17, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Human cancer, PTEN and the PI-3 kinase pathway

Ramon Parsons1

  • 1Department of Pathology and Medicine, Institute for Cancer Genetics, Columbia University, 1150 St. Nicholas Avenue, RBP 302, New York, NY, USA. rep15@columbia.edu

Seminars in Cell & Developmental Biology
|June 24, 2004
PubMed

Insights

The Phosphoinositide 3-kinase (PI-3K) pathway drives human cancers. PTEN tumor suppressor inactivation, through mutation or epigenetic changes, stimulates this pathway, offering new therapeutic targets for cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The Phosphoinositide 3-kinase (PI-3K) pathway is a critical regulator of cell growth, proliferation, and survival.
  • This pathway is frequently hyperactivated in various human cancers, acting as a major driving force for tumorigenesis.
  • The PTEN (phosphatase and tensin homolog) tumor suppressor is a key negative regulator of the PI-3K pathway.

Purpose of the Study:

  • To elucidate the mechanisms by which PTEN tumor suppressor inactivation contributes to PI-3K pathway activation in human cancers.
  • To enhance the understanding of PTEN's role in cancer etiology and PI-3K signaling.
  • To identify novel therapeutic targets based on the dysregulation of PTEN and the PI-3K pathway.

Main Methods:

  • Review and synthesis of existing literature on PTEN regulation and PI-3K pathway signaling in cancer.
  • Analysis of genetic and epigenetic alterations affecting PTEN function.
  • Investigation of post-translational modifications influencing PTEN activity.

Main Results:

  • PTEN inactivation, through mechanisms including mutation, epigenetic silencing, and post-translational modifications, is a common event leading to PI-3K pathway stimulation.
  • Dysregulation of PTEN significantly contributes to the development and progression of various human tumors.
  • Detailed understanding of PTEN regulation provides insights into PI-3K pathway's role in cancer.

Conclusions:

  • PTEN inactivation is a pivotal mechanism for activating the PI-3K pathway in human cancers.
  • Targeting PTEN and the PI-3K pathway holds promise for novel cancer therapies.
  • Further research into PTEN regulation deepens our understanding of cancer pathology and etiology.

More Related Videos

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...